$MNKD Mannkind's Drug Candidate Pipeline has seen multiple changes over the years and that's a sign of indecisiveness and inexperience. Spin out R&D into a separate company under the leadership of a competent CEO and merge exising Orphan Lung and Endocrine platforms with United Thereapeutic's who has a top notch CEO to maximize their value.
2
3
3 Likes